相关实验视频

Updated: Jul 28, 2025

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Published on: May 14, 2021

转移素向级别纳米平台用于抑制转录因子核因子红状腺2-相关因子2和增强铁质灭抗癌疗法

Wenjie Chen¹, Li Xie¹, Can Lv¹

¹Key Laboratory of Luminescence Analysis and Molecular Sensing, Ministry of Education, College of Pharmaceutical Sciences, Southwest University, 2 Tiansheng Road, Beibei District, Chongqing 400715, China.

ACS applied materials & interfaces

|May 30, 2023

概括

这项研究介绍了一种新的纳米平台,该纳米平台将铁灭症诱导剂与Nrf2抑制剂结合起来. 这种方法通过增加活性氧物种 (ROS) 来提高癌细胞死亡,以改善铁疗法.

科学领域:

生物医学工程生物医学工程
纳米技术纳米技术
癌症治疗癌症治疗

背景情况:

铁,一种依赖于铁的细胞死亡,是一个有前途的抗癌策略.
核素红细胞2-关联因子2 (Nrf2) 激活通过减少活性氧物种 (ROS) 来阻碍铁化.

研究的目的:

开发一个有针对性的纳米平台,以克服Nrf2介导的耐药性,并增强癌症治疗的铁化.
使用转移素向的中孔多多巴胺纳米平台 (TPM@AM) 同时提供铁亡诱导剂 (artsunate) 和Nrf2抑制剂 (ML385).

主要方法:

设计了一个转移素 (Tf) 向的半孔多多巴胺 (MPDA) 纳米平台 (TPM@AM).
同封装的阿尔特苏纳酸 (ART) 作为铁灭诱导剂和ML385作为Nrf2抑制剂.
利用瘤微环境的酸度和激光照射来触发药物释放和光热效应.

主要成果:

该纳米平台通过转移素受体 (TfR) 识别专门针对癌细胞.
控制释放的ART和ML385增强了细胞内ROS的积累.
MPDA提供光热能力,有助于协同抑制瘤.

结论:

TPM@AM纳米平台为精确的协同癌症治疗提供了一个空间时间控制的策略.
这种方法通过克服Nrf2介导的耐药性,有效地增强了铁疗法.
这项研究表明,通过向药物输送和组合疗法来提高抗癌疗效的有希望的方法.

关键词:

Nrf2 没有任何问题.抗癌疗法是一种抗癌疗法.工业化产品的使用铁性化 (ferroptosis) 是一种转移林是一种转移素.

更多相关视频

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Published on: March 15, 2024

Ferritinophagy: Assessing the Selective Degradation of Iron by Autophagy in Human Fibroblasts

Ferritinophagy: Assessing the Selective Degradation of Iron by Autophagy in Human Fibroblasts

Published on: February 23, 2024

相关概念视频

The Early Endosome: Endocytosis of Transferrin

The Early Endosome: Endocytosis of Transferrin

Essential proteins such as insulin or low-density lipoprotein (LDL) and micronutrients such as iron enter a eukaryotic cell through receptor-mediated endocytosis. Subsequently, the early endosomes fuse with the vesicles containing such receptor-ligand complexes and play a vital role in sorting the incoming ligands and receptors. While the ligands are either degraded inside the vesicle or released into the cytosol, their receptors are returned to the plasma membrane for further rounds of...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Necrosis

Necrosis

Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...